Be a part of 5^th International Meeting on Breast Cancer & Therapies

1. Advances in Early Detection & Screening:
Early detection significantly improves survival and treatment outcomes in breast cancer. Emerging technologies like 3D mammography, breast MRI, and molecular imaging are enhancing accuracy and reducing false positives. Artificial intelligence (AI) is revolutionizing image interpretation, providing faster and more precise diagnosis. Non-invasive tools such as liquid biopsies and circulating tumor DNA analysis are gaining prominence as future screening methods. This track will highlight the balance between early diagnosis and avoiding overdiagnosis, while also exploring how genetic risk assessment and population-based strategies can improve detection rates worldwide.
Sub-tracks: AI & Digital Imaging in Mammography: Liquid Biopsy & Biomarker-Based Screening: Contrast-Enhanced Imaging & MRI Advances: Genetic & Familial Risk Assessment: Public Health & Population Screening Programs

2. Molecular Biology & Genetics of Breast Cancer:
Understanding the genetic and molecular underpinnings of breast cancer is vital for precision medicine. Advances in genomics, transcriptomics, and epigenetics are unraveling how BRCA1/2 mutations, HER2 amplification, and other molecular markers drive cancer progression. Multi-omics approaches are offering insights into tumor heterogeneity, enabling tailored therapies. This track focuses on molecular pathways, tumor biology, and gene-environment interactions to better stratify risk and personalize treatment.
Sub-tracks: BRCA Mutations & Genetic Counseling: Multi-omics in Tumor Biology: Epigenetics & Gene Regulation: Tumor Microenvironment & Signaling Pathways: Predictive & Prognostic Biomarkers

3. Triple-Negative Breast Cancer (TNBC): Challenges & Opportunities:
TNBC remains one of the most aggressive subtypes, characterized by poor prognosis and limited treatment options. Research is advancing in targeted therapies, immune checkpoint inhibitors, and biomarker-driven clinical trials. This track will address novel therapeutic strategies, mechanisms of resistance, and how precision medicine is opening doors for TNBC management.
Sub-tracks: Molecular Subtypes of TNBC; Targeted Therapy & PARP Inhibitorsl; Immunotherapy & Immune Checkpoint Inhibitors; Mechanisms of Drug Resistance; Clinical Trials & Future Perspectives

4. Precision & Personalized Medicine in Breast Cancer: Tailoring treatment to individual patients is transforming care outcomes. Liquid biopsy, molecular profiling, and AI-driven predictive models allow clinicians to design highly personalized treatment plans. This track emphasizes the role of personalized medicine in early detection, therapy selection, and relapse prevention.
Sub-tracks: Molecular Profiling & Tumor Sequencing; AI & Predictive Analytics in Oncology; Pharmacogenomics in Breast Cancer Therapy; Real-World Applications of Precision Medicine; Personalized Screening & Follow-up Care

5. Breast Cancer Therapies: Current & Emerging: Conventional treatments such as surgery, radiation, chemotherapy, and endocrine therapy are being complemented by innovative therapies. This track will explore new strategies, combination therapies, and advances in reducing toxicity while maintaining efficacy.
Sub-tracks: Advances in Chemotherapy & Endocrine Therapy; Radiotherapy Innovations; Targeted Therapy Combinations; Nanomedicine & Drug Delivery Systems; Reducing Toxicity in Breast Cancer Treatment

6. Immuno-Oncology & Checkpoint Inhibitors in Breast Cancer: The immune system plays a central role in controlling tumor growth. Immunotherapy, especially immune checkpoint inhibitors, has shown promise in breast cancer management. This track explores novel immune targets, combination therapies, and the future of immuno-oncology.
Sub-tracks: Immune Checkpoint Inhibitors (PD-1/PD-L1, CTLA-4); CAR-T Cell Therapy in Breast Cancer; Tumor Microenvironment & Immune Modulation; Immunotherapy in TNBC; Future Immuno-Oncology Strategies

7. Surgical Advances in Breast Cancer Management: Surgery continues to be a cornerstone of treatment. Oncoplastic and minimally invasive techniques are improving cosmetic and functional outcomes. This track focuses on the role of sentinel lymph node biopsy, breast reconstruction, and innovative surgical technologies.
Sub-tracks: Oncoplastic Breast Surgery; Minimally Invasive & Robotic Techniques; Sentinel Lymph Node Biopsy & Axillary Surgery; Advances in Breast Reconstruction; Surgical Outcomes & Quality of Life

8. Radiation Oncology & Novel Delivery Methods: Modern radiation therapy techniques offer precise tumor targeting while sparing healthy tissue. Hypofractionation, proton therapy, and adaptive radiation are improving outcomes. This track examines innovations in radiation oncology and their clinical impact.
Sub-tracks: Hypofractionation in Breast Cancer; Proton Therapy & Advanced Modalities; Adaptive Radiotherapy & Imaging Integration; Radiotherapy for Recurrent & Metastatic Disease; Radiobiology & Personalized Dosing.

9. Clinical Trials & Translational Research in Breast Cancer: Clinical trials bridge the gap between laboratory discoveries and clinical practice. This track will cover trial design, novel endpoints, translational research, and global collaboration to bring therapies from bench to bedside.
Sub-tracks: Innovative Clinical Trial Designs; Biomarker-Driven Studies; Translational Oncology & Bench-to-Bedside Research; Patient Recruitment & Diversity in Trials; Global Collaboration in Clinical Studies.

10. Metastatic Breast Cancer & Disease Progression: Metastatic breast cancer remains a leading cause of mortality. Advances in systemic therapy, palliative care, and molecular profiling are improving survival and quality of life. This track highlights strategies for managing metastases and emerging therapies.
Sub-tracks: Bone, Brain, & Visceral Metastases; Targeted & Systemic Therapies for MBC; Palliative & Supportive Approaches; Biomarkers of Disease Progression; Patient-Centered Care in Advanced Disease.

11. Breast Cancer Prevention & Risk Reduction Strategies: Prevention remains the most effective strategy to reduce global burden. This track will discuss lifestyle interventions, chemoprevention, and genetic counseling in reducing risk across populations.
Sub-tracks: Lifestyle & Nutrition in Cancer Prevention; Chemoprevention Strategies; Prophylactic Surgery & Risk Reduction; Genetic Counseling & Testing; Public Health Approaches to Prevention.

12. Survivorship, Quality of Life & Supportive Care: As survival rates improve, long-term survivorship issues gain importance. This track will address physical, emotional, and social aspects of survivorship, rehabilitation, and integrative medicine to support holistic care..
Sub-tracks: Survivorship Care Plans; Mental Health & Psychosocial Support; Rehabilitation & Physical Activity; Integrative & Complementary Medicine; Long-Term Side Effect Management.

13. Digital Health, AI & Big Data in Oncology: Digital transformation is revolutionizing oncology. AI-driven diagnostics, wearable devices, telemedicine, and big data analytics are reshaping patient care. This track examines how digital health is applied in breast cancer research and clinical practice.
Sub-tracks: AI in Diagnostics & Prognostics; Digital Tools for Patient Monitoring; Wearables & Remote Health Tracking; Big Data & Real-World Evidence; Telemedicine in Breast Cancer Care.

14. Breast Cancer in Special Populations: Breast cancer presents unique challenges in men, younger women, and during pregnancy. This track explores clinical and psychosocial considerations for special populations.
Sub-tracks: Male Breast Cancer; Breast Cancer in Young Women; Pregnancy-Associated Breast Cancer; Geriatric Breast Cancer Care; Fertility Preservation & Reproductive Health.

15. Global Disparities & Equity in Breast Cancer Care: Despite medical advances, access to care remains uneven globally. This track addresses health disparities, affordability, and strategies for equity in breast cancer prevention and treatment.
Sub-tracks: Disparities in Screening & Treatment Access; Breast Cancer Care in Low-Resource Settings; Global Health Policy & Cancer Control; Patient Advocacy & Awareness Campaigns; Strategies for Equitable Access

Breast cancer remains the most commonly diagnosed cancer among women worldwide and continues to represent a major public health challenge. According to the World Health Organization (WHO), more than 2.3 million women are diagnosed with breast cancer annually, and nearly 685,000 deaths are reported each year. Rising incidence rates, combined with increasing survivorship, underscore the urgent need for advancements in early detection, precision medicine, and accessible treatment strategies.

The global breast cancer therapeutics market is experiencing rapid growth, driven by advances in targeted therapy, immunotherapy, precision diagnostics, and digital health solutions. In 2023, the breast cancer treatment market was valued at approximately USD 28 billion and is projected to reach USD 55–60 billion by 2030, with a compound annual growth rate (CAGR) of over 10%. Emerging markets in Asia-Pacific and Latin America are also witnessing accelerated adoption of innovative therapies, fueled by government initiatives, awareness programs, and improved healthcare infrastructure.

Key industry trends include the integration of AI and big data in oncology, increased focus on triple-negative breast cancer (TNBC) therapies, growing importance of biosimilars, and a shift toward personalized medicine. Additionally, supportive care and survivorship management are becoming integral parts of treatment strategies, highlighting the holistic approach needed for long-term patient well-being.

The 5th International Meeting on Breast Cancer & Therapies in Paris will provide an essential platform for discussing these market dynamics, fostering collaborations between academia, healthcare providers, policymakers, and industry leaders to shape the future of breast cancer care globally.